Healthcare

The quarterly release is the identified trigger.Leadershiplifted its 2026 revenue forecast to USD 68 million to USD 70 million, up from USD 62 million to USD 66 million, and nudged its gross margin view to above 60%, versus a previous 58% to 61%, while …

Without news, the move may be mechanical. Generally, a share trading far below USD 1.00 can rebound when short sellers close positions, when a handful of retail buyers hit a thin order book, or when a peer in oncology rallies and lifts related names. …

IceCure makes the ProSense cryoablation system, a device that freezes tumours. Earlier published coverage linked a 203% single-day spike to US ProSense uptake that rose 70%. SmallMedTechnames often jump on regulatory decisions, reimbursement shifts, installation tallies or conference talks, and retail traders can push …

Nothing from the company dated November 9 or 10, 2026, whether a release or a filing, appears in published coverage, so there is no named trigger. Recent corporate events include a USD 50 million share offer that drew moreDemandthan supply, priced on August 31, …

Key HighlightsIambic Therapeutics (NASDAQ:IAM) sat at USD 14.81 pre-market on Tuesday, November 10, 2026, up 10.69%, with the prior close, calculated at USD 13.38, set in the November 9 session.The stock priced its IPO at USD 16.00 on October 15, 2026, selling 9.375 million …

As general context, pre-revenue device companies frequently trade on regulatory updates,Patentannouncements, financing news and technical rebounds. Autonomix is building a catheter-based platform for nerve sensing and ablation, and a 510(k) route can shorten the path to US clearance relative to a full premarket approval. …

As general context, a reverse split reduces the share count and lifts the quoted price without changing the value of a holding, and many post-split stocks drift lower as holders sell. Liminatus completed a 1-for-50 split after a Nasdaq delisting notice in May 2026, …